{"schema_version":"secwatch.filing_event.v1","accession":"0000914475-22-000028","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2022-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.367740+00:00","generated_at":"2026-06-25T08:29:12.610927+00:00","sec_items":["5.02","5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Neurocrine shareholders approve equity plan amendments, elect directors at 2022 annual meeting","bullets":["Three Class II directors elected: Richard Pops, Shalini Sharp, Stephen Sherwin; each received >72M votes.","Advisory vote on executive compensation passed with 92.76% support.","Amended and restated 2020 Equity Incentive Plan and ESPP approved (89% and 99.6% of votes cast, respectively).","Ernst & Young LLP ratified as independent auditor for fiscal 2022 with 93.28% approval."],"urls":{"canonical":"https://secwatch.observer/filing/0000914475-22-000028","json":"https://secwatch.observer/filing/0000914475-22-000028.json","markdown":"https://secwatch.observer/filing/0000914475-22-000028.md","text":"https://secwatch.observer/filing/0000914475-22-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000028/0000914475-22-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000091447522000028/nbix-20220518.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T08:29:12.610927+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}